(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Wellness Bits of knowledge Readily available: A Survey of \Following Wellbeing and Progress\ Wellness Wearables - 2Grasping Wrongdoings and Crimes: A Correlation
- 3Birds at a college changed beak shapes during the pandemic. It might be a case of rapid evolution
- 45 Arising Professions in Environmentally friendly power
- 5Mossad unveils network of Hamas terror infrastructure across Europe
- 5 Different ways Macintosh is Prepared to Overwhelm Gaming, Even Against Windows
- Manual for 6 famous sorts of cheddar
- If you want a true taste of Italian paradise, head to Favignana
- Pick the Ideal Family Feline Variety for Your Home
- Fisherman Attacked by Great White Shark Says ‘My Left Foot Was in His Mouth’
- Vagus nerve stimulation shows promise as a way to counter Alzheimer’s disease- and age-related memory loss
- She just became the first wheelchair user to travel to space
- 10 Famous Frozen yogurt Flavors All over The Planet
- These Are the Journalists Israel Has Killed Since the Start of the Iran War
